Veeva and BioMarin Establish Long-term Strategic Partnership to Enhance Therapeutics Development

Veeva and BioMarin Announce a Long-term Strategic Partnership

In an exciting development for the life sciences industry, Veeva Systems (NYSE: VEEV) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) have announced a long-term corporate partnership, building on their successful history of collaboration. This agreement is aimed at enhancing the speed and operational efficiency of BioMarin’s drug development processes, aligning perfectly with its mission of bringing innovative therapies to patients faster and more effectively.

Accelerating Innovation in Drug Development

Both Veeva and BioMarin are confident that this strategic partnership will enable BioMarin to increase its agility while optimizing interactions with medical professionals and patients alike. Veeva’s suite of software, data services, and consulting products will play a crucial role in streamlining processes and improving healthcare outcomes. The integration of these technologies is set to make a significant impact, enhancing the experience of stakeholders in the drug development lifecycle.

Alexander Hardy, President and CEO of BioMarin, stated, "This strategic partnership marks a significant next step in our digital evolution. By combining our scientific expertise with Veeva's technological leadership, we believe we will be able to deliver our transformative drugs to patients around the world more quickly."

A Partnership Built on Shared Values

Echoing Hardy’s sentiments, Veeva’s CEO, Peter Gassner, expressed his enthusiasm for the continued collaboration. He emphasized that the partnership is fundamentally rooted in shared values such as product quality, value creation, and customer success. As both companies progress, Gassner looks forward to enhancing support for BioMarin in developing critical new medications and reaching greater numbers of patients around the globe.

Who are BioMarin and Veeva?

BioMarin is a leading biotechnology company recognized for its achievements in developing treatments for individuals with genetically defined diseases. Founded in 1997 and headquartered in San Rafael, California, the company has a proven track record of innovation, boasting eight commercial therapies and a robust pipeline of clinical and preclinical initiatives. BioMarin's unique approach to drug discovery and development aims to harness the full potential of genetics, creating groundbreaking medications that can profoundly affect patients’ lives.

On the other hand, Veeva is the premier cloud provider for the life sciences industry, delivering software, data, and consulting solutions. With a commitment to innovation and customer success, Veeva has surpassed 1,500 customers, ranging from the largest global biopharmaceutical companies to emerging biotech firms. As a Public Benefit Corporation, Veeva strives to align the interests of all stakeholders, ensuring the company acts in the best interests of its customers, employees, shareholders, and the industries it serves.

Looking Ahead

This partnership not only signifies a marked advancement in BioMarin's efforts to expedite its medication development but also reflects a broader trend in the life sciences industry where collaboration and technological innovation are essential. As both companies look towards the future, the potential for achieving significant breakthroughs in drug development has never been more promising.

In conclusion, Veeva Systems and BioMarin Pharmaceutical are stepping forward together in a journey that could not only enhance their operational efficiencies but also ultimately save lives through accelerated access to revolutionary therapies. As the industry evolves, partnerships such as these will play a fundamental role in shaping the future of healthcare.

For more detailed information about BioMarin, visit www.biomarin.com and for insights on Veeva’s offerings, check out veeva.com.